Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Cumberland Pharmaceuticals(CPIX.US) Q1 2024 Earnings Conference
The following is a summary of the Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript:Financial Performance:Cumberland Pharmaceuticals reported Q1 2024 net revenues of $8.5 million
Cumberland Pharmaceuticals | 10-Q: Quarterly report
Express News | Cumberland Q1 Adj $(0.05) Down From $0.11 YoY, Sales $8.50M Down From $9.22M YoY
Express News | Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update
Express News | Cumberland Pharmaceuticals Q1 Adjusted EPS USD -0.05
Express News | Cumberland Pharmaceuticals Q1 Revenue USD 8.5 Million
Express News | Cumberland Pharmaceuticals Q1 Net Income USD -1.9 Million
Express News | Cumberland Pharmaceuticals Q1 Operating Expenses USD 10.4 Million
Cumberland Pharma 1Q Loss/Shr 14c >CPIX
Cumberland Pharma 1Q Loss/Shr 14c >CPIX
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financ
Global MRSA Drugs Market Research Report 2023-2032 Featuring AbbVie, Basilea Pharmaceutica, Crystal Genomics, Cumberland Pharmaceuticals, Melinta Therapeutics, Paratek Pharmaceuticals, and Pfizer
The "MRSA Drugs Market by MRSA Type, Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032" report has...
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2023 Earnings Call Transcript
Cumberland Pharmaceuticals Full Year 2023 Earnings: US$0.44 Loss per Share (Vs US$0.38 Loss in FY 2022)
Earnings Call Summary | Cumberland Pharmaceuticals(CPIX.US) Q4 2023 Earnings Conference
The following is a summary of the Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript:Financial Performance:Cumberland Pharmaceuticals reported Q4 net revenue of $9.4 million, obse
Cumberland Pharma 4Q Rev $9.35M >CPIX
Cumberland Pharma 4Q Rev $9.35M >CPIX
Express News | Cumberland Pharmaceuticals Q4 2023 Adj. EPS $(0.11) Down From $(0.05) YoY; Revenue $9.353M Up From $9.123M Est
Cumberland Pharmaceuticals Non-GAAP EPS of $0.17, Revenue of $40M
Press Release: Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results PR Newswire NASHVILLE, Tenn., March 5, 2024 2023 highlights include expanded FDA approval and new study publications NASHVILLE, Ten
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. • Target (NYSE:TGT) is estimated to report quarterly earnings